Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05976646 · ClinicalTrials.gov registry record · Phase 1

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

A Phase 1 study, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT05976646 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05976646, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

The overall goal of this project is to collect initial human data on the effects of novel compounds on safety (interactions with an opioid drug, e.g., buprenorphine) and early efficacy signals (subjective effects on negative affect, craving, and opioid withdrawal) in OUD subjects currently in MOUD treatment with buprenorphine.

Interventions

  • DRUG Placebo
  • DRUG Auvelity

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-09-18
Est. Completion 2025-07-09
Phase Phase 1

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT05976646

The ClinicalTrials.gov registry entry for NCT05976646 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05976646 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05976646 about?

NCT05976646 is a clinical study titled "Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion". The overall goal of this project is to collect initial human data on the effects of novel compounds on safety (interactions with an opioid drug, e.g., buprenorphine) and early efficacy signals (subjective effects on negative affect, craving, and opioid withdrawal) in OUD subjects currently in MOUD t...

What is the current status of trial NCT05976646?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-09-18. Estimated completion is 2025-07-09.

What interventions are being tested in trial NCT05976646?

The interventions under investigation include: Placebo (DRUG), Auvelity (DRUG).

Who is sponsoring clinical trial NCT05976646?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.